Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$223,858 | -$146,962 | -$154,808 | -$100,217 |
| Dep. & Amort. | $7,373 | $3,565 | $2,977 | $2,397 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $55,012 | $43,118 | $35,480 | $24,972 |
| Change in WC | -$23,970 | $9,253 | -$37,623 | -$61,923 |
| Other Non-Cash | -$9,058 | -$11,800 | $889 | $5,825 |
| Operating Cash Flow | -$194,501 | -$102,826 | -$153,085 | -$128,946 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$12,838 | -$34,480 | -$2,836 | -$1,597 |
| Net Acquisitions | $0 | $0 | -$20,519 | $5,807 |
| Inv. Purchases | -$901,226 | $0 | -$445,972 | -$456,404 |
| Inv. Sales/Matur. | $496,004 | $0 | $469,327 | $358,166 |
| Other Inv. Act. | $13,983 | $174,366 | $20,519 | -$5,807 |
| Investing Cash Flow | -$404,077 | $139,886 | $20,519 | -$99,835 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$1,576 | -$76 | -$1,130 | -$849 |
| Stock Issued | $596,619 | $0 | $149,825 | $243,106 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $13,808 | $4,268 | $4,304 | $8,023 |
| Financing Cash Flow | $608,851 | $4,192 | $152,999 | $250,280 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $10,273 | $41,252 | $20,433 | $21,499 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $115,777 | $74,525 | $54,092 | $32,593 |
| End Cash | $126,050 | $115,777 | $74,525 | $54,092 |
| Free Cash Flow | -$207,339 | -$137,306 | -$155,921 | -$130,543 |